Additional Information

Description
Wegovy® (semaglutide) injection is an FDA-approved prescription medication for long-term weight management. The 1.7 mg dose is typically reached after a 16-20 week dose-escalation schedule (starting from 0.25 mg) to improve gastrointestinal tolerability. It is a therapeutic maintenance dose, and patients may continue on this dose or escalate to the 2.4 mg dose based on clinical response, tolerability, and the advice of their prescriber only. 

It is a therapeutic equivalent to other Wegovy® pens of the same strength and should not be confused with compounded semaglutide products. Dispensed only pursuant to a valid prescription. For subcutaneous injection once weekly in the abdomen, thigh, or upper arm. Dosing must be determined and supervised by a qualified healthcare professional.

Important Safety Information
This is an FDA-approved drug with an established safety profile. However, it carries a BOXED WARNING about the risk of thyroid C-cell tumors in rodents; the human relevance is unknown. Wegovy® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) . Other serious side effects may include pancreatitis, gallbladder problems, hypoglycemia, and kidney injury . Patients should be counseled on the full safety information.